Beta-thalassemia gene therapy by Contreras Garcia, Maria & Universitat Autònoma de Barcelona. Facultat de Biociències
Contreras Garcia, Maria. (maria.contreras.1991@gmail.com) 
 Biosciences Building, Autonomous University of Barcelona.  
Introduction 
Beta-thalassemia is one of the most common autosomic monogenic recessive diseases worldwide. Individuals suffering from the most severe forms of the disease suffer from life-threatening 
anemia, hepatosplenomegaly and many more. As they do not produce enough hemoglobin, they need blood transfusions frequently. However, blood transfusions provoke an iron overload with 
several worrying side effects. Bone marrow transplant is the only lifelong cure option, but this treatment is not available for patients who don’t have an HLA matched donor; Gene Therapy offers 
a new treatment alternative, making autologous cell transplant possible.  
Materials and methods 
Being Beta-thalassemia a monogenic disease, is easy to imagine why it was the target of some of the first Gene Therapy studies. The approach it offers consists in an autologous bone marrow 
transplant, as the image shows, performed after the patient cells are modified ex-vivo with a viral vector.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
The first relevant clinical trial was initiated in 2007 in France. It was directed 
towards the use of a beta-globin lentiviral vector for the treatment of individuals, 
the vector encoded the beta-globin mutated at amino acid 87, which enabled them 
to differentiate endogenous from vector produced hemoglobin. The vector was 
flanked with a truncated version of an insulator, the cHS4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Future prospectives 
 
•More Clinical trials are being made or will start in a foreseeable future, with similar  characteristics to 
the approach explained. The treatments are based in diverse beta-globin lentiviral vectors which differ 
in the gene used, insulators and LCR elements. 
 
•Induced pluripotent stem cells (IPS), pave the way for effective gene therapy application in humans. 
They could be screened for safe integration sites or corrected by gene targeting, and they expand in 
vitro and differentiate into transplantable HSC. In addition, they provide the opportunity of performing 
gene correction instead of gen addition, so there is no possibility of insertional mutagenesis. However, 
nowadays, it is necessary to improve systems for reprogramming adult cells and redifferentiation.  
 
Conclusions 
 
•Successful preclinical studies, safety increase of 
vectors due to  insulators, specific promoters and 
SIN vectors, and the amount of data available 
support the initiation of several clinical trials.  
 
•The optimal vector design, pretreatment for 
achieving engraftment, and other factors are still 
unknown; thus, further studies should be 
addressed to solve them. 
 
•IPS cells, and other new approaches help  
improving gene therapy and make it a real option. 
 
•The great potential for beta-thalassemia gene 
therapy is still to be reached, rationally designed 
clinical trials could help to achieve it . 
 
Lentivirus vectors are the ones 
used to carry the HBB gene to 
the target cells. They integrate 
into the hosts genome of both 
dividing and non-dividing cells; 
that is particularly important 
when targeting HSC, as they 
are quiescent. Retroviral
vectors do not achieve 
efficiencies as high as lentiviral 
vectors due to their inability to 
transduce non-dividing cells. In 
addition, their integration
pattern is more dangerous 
than lentivirus pattern. 
The target cells are hematopoietic stem cells (HSC) for their capacity 
of self-renewal and giving rise to different mature lineages. 
Nevertheless, this characteristics make the integration of the vector 
essential to ensure the therapeutic gene is in all progeny.  
Pretreatment is 
necessary to achieve 
therapeutic levels of 
beta-globin. As 
corrected cells do not 
experience a selective 
pressure, the effect of 
the therapy risks to 
become diluted. For 
this reason,  ablative 
myelosuppression is 
administered to the 
patients in order to 
extinguish the disease 
burden and open the 
bone marrow niche are 
being studied. 
The lentiviral vector used is a self 
inactivating vector (SIN). Deletion of 
enhancers in the viral LTRs allows for 
tighter regulation of the transgene 
and reduces the potential for 
activating close proto-oncogenes.  
The coding cassette is optimized for expression 
and size, and it is included in antisense direction 
relative to vector transcription. 
High level globin expression requires from a regulatory element
upstream of the beta globin locus (LCR), as the LCR is too large,
only core derivatives of have been introduced. 
The vector is flanked by chromatin 
insulators, in order to further 
improve vector expression and 
reduce the chance of activating 
surrounding cellular genes. 
The autologous cells were harvested 
from bone marrow and patients were 
conditioned with full myeloablation. A 
patient who followed the treatment, 
dependent on monthly transfusions, 
become transfusion independent for 
over a year. 
Most of the therapeutic benefits 
resulted from a dominant clone in 
which the integrated vector caused 
the activation of the proto-
oncogen HMGA2. Nevertheless, 
The overexpression of HMGA2 is 
correlated with benign tumour 
phenotypes. 
